LC-MS metabolomics of psoriasis patients reveals disease severity-dependent increases in circulating amino acids that are ameliorated by anti-TNFα treatment by Kamleh, Muhammad Anas et al.
Kamleh, Muhammad Anas and Snowden, Stuart G. and Grapov, Dmitry 
and Blackburn, Gavin J. and Watson, David G. and Xu, Ning and Ståhle, 
Mona and Wheelock, Craig E. (2015) LC-MS metabolomics of psoriasis 
patients reveals disease severity-dependent increases in circulating 
amino acids that are ameliorated by anti-TNFα treatment. Journal of 
Proteome Research, 14 (1). pp. 557-566. ISSN 1535-3907 , 
http://dx.doi.org/10.1021/pr500782g
This version is available at http://strathprints.strath.ac.uk/60158/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (http://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any correspondence concerning this service should be sent to the Strathprints administrator: 
strathprints@strath.ac.uk
The Strathprints institutional repository (http://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research 
outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the 
management and persistent access to Strathclyde's intellectual output.
LC−MS Metabolomics of Psoriasis Patients Reveals Disease Severity-
Dependent Increases in Circulating Amino Acids That Are
Ameliorated by Anti-TNFα Treatment
Muhammad Anas Kamleh,†,⊥ Stuart G. Snowden,†,⊥ Dmitry Grapov,‡ Gavin J. Blackburn,§
David G. Watson,§ Ning Xu,∥ Mona Stah̊le,*,∥ and Craig E. Wheelock*,†
†Department of Medical Biochemistry and Biophysics, Division of Physiological Chemistry 2, Karolinska Institutet, SE-17177
Stockholm, Sweden
‡NIH West Coast Metabolomics Center, University of California, Davis, California 95616, United States
§Strathclyde Institute of Pharmacy and Biomedical Science, 161 Cathedral Street, Glasgow G4 0RE, United Kingdom
∥Dermatology Unit, Department of Medicine, Karolinska Institutet, SE-17176 Stockholm, Sweden
*S Supporting Information
ABSTRACT: Psoriasis is an immune-mediated highly hetero-
geneous skin disease in which genetic as well as environmental
factors play important roles. In spite of the local manifestations of
the disease, psoriasis may progress to aﬀect organs deeper than
the skin. These eﬀects are documented by epidemiological
studies, but they are not yet mechanistically understood. In order
to provide insight into the systemic eﬀects of psoriasis, we
performed a nontargeted high-resolution LC−MS metabolomics
analysis to measure plasma metabolites from individuals with
mild or severe psoriasis as well as healthy controls. Additionally,
the eﬀects of the anti-TNFα drug Etanercept on metabolic
proﬁles were investigated in patients with severe psoriasis. Our
analyses identiﬁed signiﬁcant psoriasis-associated perturbations in
three metabolic pathways: (1) arginine and proline, (2) glycine, serine and threonine, and (3) alanine, aspartate, and glutamate.
Etanercept treatment reversed the majority of psoriasis-associated trends in circulating metabolites, shifting the metabolic
phenotypes of severe psoriasis toward that of healthy controls. Circulating metabolite levels pre- and post-Etanercept treatment
correlated with psoriasis area and severity index (PASI) clinical scoring (R2 = 0.80; p < 0.0001). Although the responsible
mechanism(s) are unclear, these results suggest that psoriasis severity-associated metabolic perturbations may stem from
increased demand for collagen synthesis and keratinocyte hyperproliferation or potentially the incidence of cachexia. Data
suggest that levels of circulating amino acids are useful for monitoring both the severity of disease as well as therapeutic response
to anti-TNFα treatment.
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■ INTRODUCTION
Psoriasis is an immune-mediated skin disease associated with
signiﬁcant morbidity and mortality.1 The ultimate cause of
psoriasis remains unclear, but it involves triggering the immune
system, leading to sustained inﬂammation and dysregulation of
keratinocyte diﬀerentiation.2 Psoriasis is a heterogeneous
disease with signiﬁcant comorbidities including, in particular,
psoriatic arthritis.3−5 Genome-wide association studies indicate
a large genetic component in the pathogenesis of psoriasis.6 In
particular, the HLA-C gene is estimated to contribute ∼50% to
the heritability in early onset psoriasis.7 Once activated,
dendritic cells stimulate diﬀerentiation and migration of Th1
and Th17 eﬀector T cells to the skin, which, through cytokine
release, immune cell recruitment, and keratinocyte prolifer-
ation, drive a sustained cycle of chronic inﬂammation.8 Patients
with psoriasis are also at a signiﬁcant risk of developing
metabolic syndrome, type 2 diabetes, hypertension, and
obesity.9−11 The underlying mechanisms are still unclear, and,
to date, comorbidities are supported primarily by epidemio-
logical data.12
The cytokine tumor necrosis factor alpha (TNFα) is known
to play a major role in the pathophysiology of psoriasis,13 and
anti-TNFα therapeutics are routinely used to treat immune-
mediated diseases including psoriasis as well as psoriatic and
rheumatoid arthritis in adult as well as pediatric populations.5,14
One of the ﬁrst-line anti-TNFα treatments is the biologic
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Etanercept, which has demonstrated eﬃcacy in resolving
psoriatic lesions. Etanercept is a fusion protein that binds to
the constant end of the IgG1 antibody5,15 and acts as a
competitive inhibitor of TNFα. Although it signiﬁcantly
suppresses the associated inﬂammation, Etanercept, as well as
other biologic therapeutics, does not cure the underlying
disease.16 TNFα is also involved in other physiological
processes such as muscle protein proteolysis and cachexia,17
thereby suggesting additional pathways by which anti-TNFα
therapeutics may aﬀect the underlying pathophysiology of the
disease.
In order to investigate the systemic biochemical shifts
associated with disease severity, liquid chromatography high-
resolution mass spectrometry (LC−HRMS) metabolomic
analysis was used to characterize circulating metabolites in
psoriasis patients. Metabolomics proﬁles were also compared
before and after a 12 week treatment with Etanercept. A
metabolomics-based research approach involves simultaneously
analyzing the complement of small molecules (metabolites) in a
system. This has been shown to be useful for identifying
metabolic traits that represent intermediate phenotypes capable
of linking genetic and environmental factors to heterogeneous
diseases.18,19 This study is, to the best of our knowledge, the
ﬁrst to examine the metabolic proﬁle associated with plaque
psoriasis severity and the eﬀects of Etanercept treatment. These
results provide insight into the biochemical pathways involved
in the etiology of psoriasis and the systemic eﬀects of
Etanercept treatment.
■ EXPEREMINTAL SECTION
Study Design
Healthy controls as well as patients with mild or severe
psoriasis were recruited at the Karolinska University Hospital.
Mild psoriasis patients were recruited from a cohort of patients
with newly onset psoriasis who did not require systemic therapy
and were therefore treated only topically. Severe psoriasis
patients required systemic therapy to control the skin
manifestations of the disease. None of the patients were on
statins or prescribed anti-inﬂammatory drugs. All samples were
obtained prior to the commencement of any treatment. The
recruitment group consisted of 96 gender-balanced individuals
(32 healthy controls and 32 mild and 32 severe psoriasis). For
analysis purposes, the full cohort (n = 96) was subdivided into
two gender- and disease severity-balanced groups (n = 48
each), called exploratory and validation cohorts (Table 1). The
exploratory cohort was used to identify metabolic markers for
psoriasis severity, and the validation cohort as a conﬁrmation of
the identiﬁed trends. Additional plasma samples were taken
from the severe psoriasis patients (n = 16) in the validation
cohort following 12 weeks of Etanercept (Enbrel) treatment
(50 mg once per week subcutaneously), and this group is
referred to as the treatment cohort. For blood collection, 10 mL
of whole blood was collected in EDTA tubes after overnight
fasting. Samples were left standing for 1 h before centrifugation
at room temperature for 20 min at 3100 rpm. After
centrifugation, samples were aliquoted and immediately stored
at −70 °C until use. Psoriasis disease was judged as severe
when it required systemic therapy and was evaluated by the
psoriasis area and severity index (PASI), which is an established
measurement that quantiﬁes the thickness, redness, scaling, and
distribution of psoriasis lesions.20 The study was approved by
the Regional Committee of Ethics and was performed
according to the Declaration of Helsinki Principles. Signed
consent forms were collected from all sample donors.
HILIC Mode Metabolomics
A cocktail of four internal standards (10 μL; Table S1) was
added to 50 μL of EDTA plasma. Proteins were precipitated
using 200 μL of HPLC grade acetonitrile (Rathburn). Samples
were vortexed for 5 s and then left to stand on ice for 10 min
followed by centrifugation at 15 000 rcf for 10 min at 4 °C. The
supernatant (150 μL) was transferred to a clean Eppendorf
tube, and 20 μL of each sample was used to produce a pooled
quality control. Samples were stored at −20 °C prior to
analysis. Prepared samples were analyzed on a Thermo
Ultimate 3000 HPLC and Thermo Q-Exactive (Orbitrap)
mass spectrometer. Ten microliters of sample was injected on a
Merck Sequant ZIC-HILIC column (150 × 4.6 mm, 5 μm
particle size) coupled to a Merck Sequant ZIC-HILIC guard
column (20 × 2.1 mm). Mass spectrometry data were acquired
(full scan mode) in both positive and negative ionization
modes, using 140 000 mass resolution.
Reversed-Phase (RP) Metabolomics
A cocktail of ﬁve internal standards (10 μL; Table S1) was
added to 50 μL of EDTA plasma followed by 150 μL of chilled
(−20 °C) methanol (Rathburn) for protein precipitation.
Samples were vortexed for 5 s and left to stand for 2 h at −20
°C, followed by centrifugation at 15 000 rcf for 12 min at 4 °C.
The supernatant (90 μL) was transferred to a clean Eppendorf
tube, and 10 μL of each sample was used to produce a pooled
quality control. On the analysis day, samples were diluted 1:1
with Milli-Q water (Millipore). Prepared samples were analyzed
on a Thermo Ultimate 3000 HPLC and Thermo Q-Exactive
(Orbitrap) mass spectrometer. Twenty microliters of sample
was injected on a Thermo Accucore aQ RP C18 column (150
× 2.1 mm, 2.7 μm particle size). Mass spectrometry data were
acquired (full scan mode) in both positive and negative
ionization modes, using 70 000 mass resolution. Detailed
methods are provided in the Supporting Information.
Data Processing and Metabolite Annotation
RAW ﬁles were converted to universal mzXML ﬁle using
MSconvert.21 All chromatograms were evaluated using the
open source software package XCMS22 performed in R.23 For
the preliminary analysis, metabolites were annotated by
matching accurate mass and retention time (AMRT) to
authentic chemical reference standards. Variables of importance
identiﬁed from the multivariate analyses (see Statistical
Analysis) were subjected to further identity conﬁrmation by
comparing fragmentation patterns to those of chemical
standards. The MS/MS spectra of all reported metabolites
matched those of the standards with the exception of inosine
(which was excluded from further analysis). Data analysis was
limited to metabolites matching the AMRT and MS/MS
fragmentation spectra of standards except for sphingosine-1-
phosphate and GlcCer(C16:0), which were identiﬁed only by
AMRT. The coeﬃcient of variance (CV) of the HILIC internal
standard cocktail was <35%, and for reversed-phase, <15%. All
CVs of the discussed metabolites were <30%, except for
cystathionine and cytidine (exploratory and validation cohorts)
and cysteine and proline (validation cohort only). The median
CV for the identiﬁed metabolites was 14.8 and 16.0% for the
exploratory and validation cohorts, respectively.
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Statistical Analysis
Statistical analysis was used to identify signiﬁcantly altered
metabolites within the exploratory and validation cohorts
between (1) control and mild, (2) control and severe, (3) mild
and severe, and (4) severe pre- and post-treatment with
Etanercept (validation cohort only) psoriasis patients. Compar-
isons for 1−3 were made using two-sample t-tests, and for 4,
based on a paired t-test carried out in the R statistical
programming environment.23 The false discovery rate (FDR)
due to the multiple hypotheses tested was adjusted according to
Benjamini and Hochberg (q = 0.05)24 and reported as padj.
FDR was also directly estimated according to Dabney and
Storey25 and reported as the q-value.
Multivariate analysis was performed using a combination of
principal component analysis (PCA) and orthogonal projection
to latent structures−discriminant analysis (OPLS-DA) using
SIMCA-P 13 (Umetrics, Umea,̊ Sweden). OPLS-DA was
conducted following logarithmic transformation (base 10),
mean centering, and scaling to unit variance (UV). OPLS-DA
model performance was evaluated based on the cumulative
coeﬃcient of correlation between group labels (Y) and model
projection of metabolites (X) (R2Ycum) and 7-fold cross-
validated model ﬁt to the data (Q2cum), the signiﬁcance of which
was assessed through cross-validation analysis of variance (CV-
ANOVA). Model predictive and orthogonal components are
reported as (predictive + orthogonal). Iterative feature selection
(2 rounds) was performed to identify important metabolic
discriminants between the compared populations. Metabolites
were retained in the model based on a combination of variable
importance in projection (VIP) > 1.0 and absolute magnitude
of correlation with model scores (pcorr > 0.4).
26 SIMCA-P was
used to calculate the PLS inner relation between disease
severity score (PASI) and correlated metabolites (|Pearson’s
correlations| > 0.5).
Pathway Enrichment Analysis
Biochemical pathway enrichment analysis was used to identify
psoriasis-dependent changes in global biochemical domains.
MetaboAnalyst27 was used to test for signiﬁcant enrichment in
KEGG pathways (http://www.genome.jp/kegg/) among the
noted metabolic perturbations in common to both the
exploratory and validation cohorts (Table 2). Signiﬁcant
enrichment was assessed on the basis of the false discovery
rate-adjusted hypergeometric test statistic (p ≤ 0.05), and
impact on pathway topology was deﬁned based on relative-
betweeness centrality.
Partial Correlation Network Analysis
Gaussian graphical model networks were calculated for
metabolite relationships in the context of the identiﬁed
diﬀerences between (1) control and severe, (2) control and
treated severe, and (3) untreated and treated severe psoriasis
patients from the validation cohort. q-order partial correlations
(q = 1, 12, 24, 35)28 were calculated (n = 1000) in R (v3.0.1)23
between metabolites (n = 93) from the validation data set,
excluding patients with mild psoriasis (n = 48). To maximize
network node inclusion and minimize edge degree, a threshold
of β = 0.4 for the average nonrejection rate (β) for metabolite
pairwise relationships was selected. Using this approach, a
smaller average nonrejection rate corresponds to stronger q-
order partial correlation. Spearman’s rank order coeﬃcients of
correlation, p-values, and FDR-adjusted p-values (padj)
24 were
calculated for all q-order selected relationships. Cytoscape29
was used to generate network visualizations for all edges
displaying padj ≤ 0.05 (83 edges or 90% of the original q-order
calculated edges). Network mapping was used to encode and
display statistical and multivariate analysis results within the
context of the partial correlation deﬁned relationships.
■ RESULTS
Psoriasis patients and control characteristics were consistent
between the exploratory and validation cohorts (Table 1). PASI
scoring signiﬁcantly increased (p < 0.05) with disease severity
in both cohorts and decreased following Etanercept treatment
(Table 1). HILIC mode and reversed-phase metabolomic
analyses of the exploratory and validation cohorts’ plasma were
used to identify 94 and 93 metabolites from the XCMS
diﬀreport of all samples, respectively (67 of which were in
common), through matching of retention time and spectra to
external standards (Table S2). Statistical analyses of the
metabolomic measurements with adjustment for FDR were
used to identify signiﬁcantly altered compounds among control,
mild, and severe psoriasis patients for both the exploratory and
validation cohorts (Tables S3 and S4) and between severe and
severe Etanercept-treated psoriasis patients in the validation
cohort (Table S4). Additionally, changes in >150 metabolite
features putatively identiﬁed based on only accurate mass are
reported for the comparisons between severe psoriasis patients
and controls in both cohorts (Tables S5 and S6) and between
severe psoriasis patients at baseline and after Etanercept
treatment (Table S7).
As expected, the largest eﬀect size was observed between
control and severe psoriasis patients, with 33 and 34
signiﬁcantly (padj ≤ 0.05) perturbed plasma metabolites in the
exploratory and validation cohorts, respectively (Tables S3 and
S4). Comparison of the psoriasis-associated metabolic alter-
Table 1. Characteristics of the Study Cohortsa
exploratory cohort
control mild severe
gender 8/8d 8/8 8/8
age (years) 52 ± 9 52 ± 8 58 ± 10
BMIb 26.1 ± 4.1 25.0 ± 4.8 28.4 ± 3.5
PASIc n/a 1.4 ± 0.7e 16.5 ± 7.4e
cholesterol 5.2 ± 0.8 5.1 ± 0.9 4.8 ± 0.9
triglycerides 1.0 ± 0.4 1.0 ± 0.56 1.3 ± 0.5
validation cohort
control mild severe
severe
(treated)f
gender 8/8 8/8 8/8 8/8
age (years) 44 ± 13 42 ± 20 53 ± 13 53 ± 13
BMI 24.0 ± 3.1 25.2 ± 4.7 27.3 ± 4.8 27.2 ± 4.6
waistline (cm) n/d n/d 98 ± 13.8 97 ± 12.9
PASI n/a 1.6 ± 1.0e 13.6 ± 4.5e 4.9 ± 3.4g
cholesterol 5.1 ± 0.8 4.9 ± 0.9 5.3 ± 0.6 6.57 ± 4.1h
triglycerides 1.1 ± 0.6 1.2 ± 1.0 1.0 ± 0.4 1.7 ± 0.9
aValues are reported as the mean ± SD. Units for cholesterol and
triglycerides are mmol/L. n/d indicates that the value was not
determined. bBMI, body mass index. cPASI, psoriasis area and severity
index. There is no PASI score for the control group (n/a). dGender
balance: male/female. ep-value < 0.05 for a two-sample t-test for the
PASI score between mild and severe psoriasis subjects. fSevere
psoriasis patients treated with Etanercept for 12 weeks. gp-value < 0.05
for a paired two-sample t-test for the PASI score for treated vs
untreated severe psoriasis. hp-value < 0.05 based on a paired t-test.
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ations in common to both cohorts identiﬁed 20 signiﬁcantly
(padj ≤ 0.05) altered metabolites, 17 of which increased with
psoriasis severity in both cohorts (Table 2). In particular,
ornithine and another urea cycle intermediate, citrulline,
increased by 215 and 90%, on average, respectively, in severe
psoriasis patients compared to that in controls (Table 2).
Etanercept treatment led to reductions in 10 of the 20 (50%)
previously identiﬁed psoriasis-associated metabolic dysregula-
tions (Table 2). Speciﬁcally, treatment resulted in signiﬁcant
reductions in amino acids, highlighted by 230, 233, and 150%
decreases in threonine, ornithine, and methionine, respectively
(Table 2). Comparison of Etanercept-treated severe psoriasis to
controls revealed a normalization in the majority (89%) of
metabolites previously shown to be increased with disease.
Although cystine was signiﬁcantly reduced by 10% following
treatment, this amino acid remained 60% elevated in the treated
group relative to that in controls (Table 2). Cystathionine was
the only metabolite in common to both cohorts that was
reduced (80%) in severe psoriasis compared to that in controls
and was not signiﬁcantly aﬀected by Etanercept treatment
(Table 2). Similarly, sphingosine-1-phosphate levels were not
aﬀected by treatment and remained 70% elevated in the treated
group (Table 2).
The relationship between psoriasis disease severity score
(PASI) and the metabolites identiﬁed in Table 2 was further
interrogated using correlation analysis and partial least-squares
(PLS) inner relation. Of the metabolites presented in Table 2,
10 correlated with psoriasis disease severity scores (r ≥ 0.5) in
either the validation or treated cohort (Table 3). A PLS inner
relation was calculated between these 10 metabolites and PASI
scores (Figure 1), producing a signiﬁcant multivariate
association (R2 = 0.80; p < 0.0001) between PASI scores
(Figure 1A) and metabolite abundances (Figure 1B).
Threonine, citrulline, and ornithine displayed the highest
positive correlation with PASI scores (Table 3), whereas
threonine, glutamine, and ornithine were the most highly
ranked multivariate predictors of psoriasis severity (Figure 1B).
Following Etanercept treatment, there was a signiﬁcant
reduction in PASI scores associated with a normalization in
all but two of the metabolites that were altered in severe
psoriasis patients within both cohorts (Table 2).
Data sets were further interrogated using multivariate
methods. PCA identiﬁed no outliers in the exploratory or
validation cohorts based on Hotelling’s T2 (i.e., 95% conﬁdence
interval) or DModX (data not shown). Multivariate classi-
ﬁcation modeling (OPLS-DA) followed by feature selection
was implemented to identify top metabolic markers for disease-
speciﬁc diﬀerences in plasma metabolite proﬁles in both
cohorts (Figure 2 and Table S8). For the exploratory cohort,
only severe psoriasis produced signiﬁcant models (p < 0.05;
mild vs severe [Q2 = 0.605]; control vs severe [Q2 = 0.741]).
For the validation cohort, all calculated models were signiﬁcant
(p < 0.001) and showed a disease severity-based increase in
circulating metabolites from control vs mild (Q2 = 0.626) to
Table 2. Fold Changes in Metabolites Associated with Severe Psoriasis That Showed Similar Patterns in the Exploratory and
Validation Cohorts
exploratory cohort validation cohort Etanercept treated cohort
severe vs controlb severe vs control treated vs severe treated vs control
pathway metabolitea q-valuec FCd q-value FC q-value FC q-value FC
arginine and proline pathwaye arginineo 1.82 × 10−2 2.47 1.43 × 10−3 2.29 7.58 × 10−3 0.45 7.48 × 10−1 1.02
citrullineo 4.09 × 10−4 2.61 1.16 × 10−5 1.88 1.46 × 10−2 0.64 4.07 × 10−1 1.19
ornithineo 6.92 × 10−3 3.37 1.77 × 10−4 2.92 2.18 × 10−3 0.41 4.07 × 10−1 1.21
prolineo 1.24 × 10−2 1.83 1.40 × 10−2 1.89 1.09 × 10−1 0.65 4.16 × 10−1 1.22
hydroxyprolineo 2.16 × 10−2 2.93 6.88 × 10−3 1.81 7.87 × 10−2 0.69 3.99 × 10−1 1.25
glycine, serine, and threonine
pathwayf
glycineo 9.42 × 10−3 2.13 2.87 × 10−3 1.68 2.18 × 10−3 0.49 3.99 × 10−1 0.83
serineo 4.74 × 10−3 1.96 1.15 × 10−4 1.61 1.35 × 10−1 0.78 3.58 × 10−1 1.25
threonineo 4.09 × 10−4 2.68 3.99 × 10−6 2.58 7.77 × 10−7 0.32 3.85 × 10−1 0.82
alanine, aspartate, and glutamate
pathwayg
aspartateo 7.66 × 10−3 2.43 2.63 × 10−5 1.96 1.39 × 10−1 0.69 3.99 × 10−1 1.34
glutamateo 1.26 × 10−2 3.00 4.80 × 10−3 2.22 3.33 × 10−1 0.78 3.58 × 10−1 1.72
glutamineo 1.75 × 10−3 2.03 4.26 × 10−4 1.71 7.34 × 10−3 0.59 7.48 × 10−1 1.02
cysteine and methionine pathwayh cystineo 4.07 × 10−3 2.81 1.77 × 10−4 1.83 2.86 × 10−1 0.9 6.07 × 10−3 1.64
cystathionineo 1.13 × 10−2 0.83 3.99 × 10−6 0.31 2.96 × 10−1 1.51 1.94 × 10−2 0.47
methionineo 1.41 × 10−2 2.15 1.77 × 10−4 1.84 4.82 × 10−5 0.42 3.58 × 10−1 0.78
taurine and hypotaurine pathwayi taurineo 2.70 × 10−4 1.92 4.96 × 10−4 1.47 1.79 × 10−1 0.82 3.38 × 10−1 1.21
phenylalanine pathwayj phenylalanineo 1.90 × 10−2 1.34 1.89 × 10−4 1.48 4.52 × 10−2 0.73 5.38 × 10−1 1.07
pyrimidine pathwayk cytidineo 7.80 × 10−3 2.09 2.55 × 10−2 2.47 2.42 × 10−1 0.65 3.58 × 10−1 1.6
amino sugar pathwayl acetylglucosamineo 6.92 × 10−3 2.36 2.90 × 10−3 1.34 7.87 × 10−2 0.72 7.12 × 10−1 0.96
sphingolipid pathwaym glucosylceramide
(C16:0)p
4.29 × 10−2 1.46 1.01 × 10−2 1.59 4.34 × 10−1 0.95 3.02 × 10−1 1.51
sphingosine-1-
phosphatep
3.54 × 10−2 1.21 1.89 × 10−4 1.93 3.06 × 10−1 0.88 2.94 × 10−2 1.69
aAll metabolites displayed were not signiﬁcantly altered in mild vs control or mild vs severe psoriasis patients in either the exploratory or validation
cohorts. bSevere psoriasis patients vs healthy controls. cFalse discovery rate (FDR) was directly estimated according to the methods of Dabney and
Storey.25 dFold change between the two groups. eKEGG Pathway map hsa00330: arginine and proline metabolism. fKEGG Pathway map hsa00260:
glycine, serine, and threonine metabolism. gKEGG Pathway map hsa00250: alanine, aspartate, and glutamate metabolism. hKEGG Pathway map
hsa00270: cysteine and methionine metabolism. iKEGG Pathway map hsa00430: taurine and hypotaurine metabolism. jKEGG Pathway map
hsa00360: phenylalanine metabolism. kKEGG Pathway map hsa00240: pyrimidine metabolism. lKEGG Pathway map hsa00520: amino sugar and
nucleotide sugar metabolism. mKEGG Pathway map hsa00600: sphingolipid metabolism. oResults obtained from HILIC analysis. pResults obtained
from reversed-phase analysis.
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mild vs severe (Q2 = 0.794) to control vs severe (Q2 = 0.891).
Etanercept treatment resulted in metabolic proﬁles that were
shifted from both severe untreated (Q2 = 0.645) and controls
(Q2 = 0.534), giving a unique pharmacological phenotype.
However, the Etanercept vs control OPLS-DA model was the
weakest of all generated models (p = 2.76 × 10−4), indicating
that the treated cohort had a metabolic proﬁle most similar to
the controls. All model statistics are provided in Table S8.
Biochemical pathway enrichment analysis of the psoriasis-
associated metabolic perturbations in common to both cohorts
(Table 2) was used to identify signiﬁcant perturbations (p ≤
0.05) in 10 major biochemical pathways (Table S9). Partial
correlation networks were calculated to analyze empirical
metabolite−metabolite relationships in the context of the
identiﬁed psoriasis-associated metabolic perturbations (Figure
3). On the basis of the network topology, the three most
psoriasis-impacted pathways were those of alanine, aspartate,
and glutamate metabolism (hsa00250); glycine, serine, and
threonine metabolism (hsa00260); and arginine and proline
metabolism (hsa00330). In particular, there was a dominant
psoriasis-dependent increase in the majority of urea cycle
intermediates including aspartate, arginine, ornithine, and
citrulline. The conﬁrmed changes in metabolites (Table 2)
are highlighted in these networks (thick borders) and can be
classiﬁed into three major correlated clusters (Figure 3A): (1)
cytidine, cystathionine, acetylglucosamine, hydroxyproline, and
taurine; (2) ornithine, arginine, threonine, methionine,
glutamine, glycine, citrulline, and proline; and (3) phenylanine,
cystine, GlcCer(C16:0), aspartate, and glutamate. Metabolic
changes within these three clusters, with the exception of
cystathionine, were positively correlated and increased with
psoriasis severity (Table 3). Etanercept treatment of severe
psoriasis patients predominantly impacted cluster 2 metabolites
(Figure 3B). Comparison of the Etanercept treated group to
healthy controls in the validation cohort (Figure 3C) revealed
normalization in the majority of the previously identiﬁed
psoriasis-associated metabolic perturbations with the exception
of cystathionine and cystine.
■ DISCUSSION
There is an extensive body of literature on psoriasis; however,
to date, there has been limited work investigating the
underlying metabolic processes associated with the disease.30
To the best of our knowledge, this is the ﬁrst study utilizing
nontargeted metabolomics to study the eﬀect of psoriasis
severity and the impact of Etanercept treatment on metabolism.
Comparisons of plasma metabolic proﬁles of psoriasis patients
suggest that the mild and severe disease states are not, from a
metabolic perspective, distinct pathologies but a progression of
Table 3. Pearson’s Correlations between Disease Severity
(PASI) and Plasma Metabolite Levelsa
metabolite
exploratory
cohortb
validation
cohortb
treated
cohortb,c
arginine 0.52** 0.50*** 0.60**
citrulline 0.73*** 0.84*** 0.70***
ornithine 0.43* 0.84*** 0.75***
proline 0.77*** 0.23 0.37*
hydroxyproline 0.20 0.43* 0.23
glycine 0.74*** 0.47*** 0.69***
serine 0.44** 0.73*** 0.55**
threonine 0.84*** 0.87*** 0.88***
aspartate 0.05 0.26 0.17
glutamate 0.33 0.42* 0.09
glutamine 0.70*** 0.66*** 0.76***
cystine 0.79*** 0.75*** 0.56**
cystathionine −0.27 −0.43 −0.19
methionine 0.39* 0.46** 0.74***
taurine 0.34 0.51** 0.22
phenylalanine 0.31 0.66** 0.37*
cytidine 0.63*** 0.36* 0.34
acetylglucosamine 0.28 0.48** 0.45*
glucosylceramide
(C16:0)
0.50** 0.34 0.19
sphingosine-1-
phosphate
0.35 0.50* 0.16
aMetabolites in the validation and treated cohorts with r ≥ 0.5 were
used for the regression with PASI score in Figure 1. Correlations
include both mild and severe psoriasis patients for both the
exploratory and validation cohorts. bThe signiﬁcance level is indicated
as follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001. The confounding
eﬀects of age and BMI were tested via a linear regression model using
STATA 11. cSevere psoriasis patients from the validation cohort were
treated with Etanercept for 12 weeks. Correlation values are only for
the treated patients.
Figure 1. PLS inner relation between the 10 metabolites identiﬁed to
correlate (r ≥ 0.5) with the psoriasis area and severity index (PASI) in
severe psoriasis patients pre- and post-treatment with Etanercept
(Table 3). (A) The inner relation for severe psoriasis and treated
severe psoriasis patients from the validation cohort (R2 = 0.80). For
untreated severe psoriasis only, R2 = 0.82; for mild psoriasis only, R2 =
0.32; and for mild, severe untreated, and treated psoriasis combined,
R2 = 0.78. For the exploratory cohort, R2 = 0.91 for severe psoriasis, R2
= 0.49 for mild and severe psoriasis combined, and R2 = 0.26 for mild
psoriasis only. (B) The variable importance in projection (VIP) plot
displaying the relative contributions of the individual metabolites to
the inner relation. S1P=sphingosine-1-phosphate.
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the disease along a shared metabolic continuum. However,
although distinct shifts in the circulatory metabolic proﬁles of
severe psoriasis patients were observed, it is unclear as to the
corresponding mechanism responsible.
Psoriasis severity was associated with an increase in three
intermediates of the urea cycle (citrulline, ornithine, and
arginine). Shifts in arginine and urea cycle metabolism have
been previously reported in psoriatic skin lesions,31 and similar
shifts in urea cycle intermediates,32 as well as changes in
glutamine and glutamate, have been associated with wound
healing.33 The commonality in markers for psoriasis and wound
healing is not surprising given that both psoriasis34,35 and
wound healing36−38 involve the production of new keratino-
cytes. The urea cycle is an entry to the pathway for the
synthesis of polayamines, which are essential hormones in cell
proliferation, a hallmark of keratinocytosis in psoriasis.39 The
polyamine requirement may promote the mobilization of the
urea cycle intermediate arginine from its sites of synthesis to
the skin, resulting in the observed enhanced plasma levels.
Protein synthesis demand in the proliferating skin could also
explain the elevated amino acid proﬁle in plasma. Psoriasis is
associated with changes in protein expression.40 Corniﬁcation
of the epidermis requires diﬀerent scaﬀolding proteins than that
in healthy cells, and a collection of support proteins such as
small proline-rich protiens (SPRP), hornirine (HNRN), and
late corniﬁed envelope 3 A (LCE3A) were elevated up to 500
times in psoriasis skin compared to that in healthy skin.40 The
production of these psoriasis-enriched proteins postulates an
enhanced inﬂux of amino acids. The requirements of this
process agree largely with the observed increases in circulating
amino acids. The most represented amino acids in the regulated
proteins in psoriasis were serine, proline, glycine, and
glutamine. This proﬁle was not altered when a score of fold
change (psoriasis vs healthy) of protein expression was
calculated (Table S10). To add to the requirement burden,
the major amino acids in human collagen 1 alpha are glycine
(27%) and proline (18%). While collagen is produced in the
dermis, which does not thicken in psoriasis, there are
indications that collagen turnover is higher in psoriasis patients,
with reported enhanced activity of collagen breakdown
enzymes prolidase41 and matrix metalloproteasease MMP142
(the latter being 13 times higher in psoriasis patients compared
to that in healthy controls). Hydroxyproline, a marker for tissue
collagen degradation,43 was upregulated in severe psoriasis
patients and normalized by Etanercept treatment. This agrees
with Garvican et al., who showed the ability of IL-1 or TNFα to
promote collagen degradation in ovine cartilage.44 The modest
correlation of hydroxyproline with PASI score may indicate
diﬀerent susceptibility of subjects, and further investigations are
necessary to examine if this susceptibility is reﬂected with
incidence of psoriatic arthritis.
Another potential explanation for the observed increase of
circulating amino acids would be due to cachexia or wasting
syndrome, which is the loss of lean body mass that can
Figure 2. OPLS-DA scores and variable importance in projection (VIP) plots from the curated models following 2 rounds of variable selection as
described in the Experimental Section. (A) Scores plot of control vs severe psoriasis in the exploratory cohort (R2Y = 0.762 Q2 = 0.741, CV ANOVA
p = 3.2 × 10−9, 1 + 0 components); (B) VIP plot of control vs severe psoriasis in the exploratory cohort; (C) scores plot of control vs severe
psoriasis in the validation cohort (R2Y = 0.895 Q2 = 0.891, CV ANOVA p = 1.1 × 10−14, 1 + 0 components); (D) VIP plot of control vs severe
psoriasis in the validation cohort. S1P=sphingosine-1-phosphate.
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accompany systemic inﬂammatory diseases.45 Cachexia has
been linked with psoriasis,46 and cytokine inhibitors (e.g., anti-
TNFα) have been suggested in the treatment of cachexia.47
TNFα in particular is thought to play a role in both the
anorexic eﬀect via neuronal leptin receptors48 as well as muscle
wasting by enhancing protein ubiquitation.49 A cachectic state
of psoriasis patients has been suggested due to a dual role of
TNF, evidenced by the increase in BMI during anti-TNFα
treated patients.50,51 Accordingly, it is possible that increased
muscle protein breakdown, a hallmark of cachexia, may explain
the higher levels of circulating amino acids observed in subjects
with severe psoriasis. Muscle wasting has been reported in
other autoimmune diseases such as rheumatoid arthritis;52
however, this may not be associated with changes in body
weight.53 In our study, BMI was marginally higher in severe
psoriasis patients (Table 1; p = 0.07), whereas the BMI values
of each subject did not change following treatment (p = 1.0).
Treatment with anti-TNFα has previously been reported to
increase BMI,54 but this was primarily due to increases in fat-
free mass, which was not examined in the current cohort.
Cachexia has not been widely studied from a metabolic
perspective, and there is no consensus on plasma levels of
metabolites in cachectic patients or animal models. Peters et al.
showed that in a tumor-bearing mouse model plasma amino
acids were upregulated.55 O’Connell et al. reported changes in
lipids, glycerol, and glucose, but not amino acids, in the plasma
of a murine cancer cachexia model.56 A follow up study
observed an increase in urea cycle amino acids and decreased
glycine, alanine, and serine in skeletal muscle.57 Ubhi et al.
observed a slightly signiﬁcant (p = 0.05−0.1) increase in plasma
amino acids of cachectic compared to noncachectic COPD
patients.58 Moreover, a number of cachectic studies exhibited
lower levels of circulating amino acids during cachexia in
clinical as well as animal studies.59−61 However, a down-
regulation of circulating branched-chain amino acids, which is
thought to be a hallmark of cachexia,62 was not observed in the
current study. Accordingly, although it is unlikely that the
observed shifts in circulating amino acids are due to cachexia,
further evaluation is warranted.
The dominant eﬀect of Etanercept treatment was observed in
normalizing the plasma levels of a large cluster of positively
correlated metabolites consisting of ornithine, arginine, proline,
citrulline, glycine, glutamine, threonine, and methionine
(Figure 3), speciﬁcally within the arginine/proline and glycine,
serine, and threonine pathways (Table S9). The biochemical
mechanism leading to the Etanercept-dependent reduction in
these metabolites is unclear. However, blocking the immune
(autoimmune) response can lead to a reduced signal for
collagen and other keratinocyte-speciﬁc structural protein
production as well as keratinocytosis, resulting in a diminished
requirement for these metabolites. Etanercept acts by inhibiting
the activity of the cytokine TNFα,15 which is involved in a wide
range of biological activities. TNFα can modulate the activity of
nitric oxide synthase (NOS),63 which is involved in the
production of nitric oxide from the conversion of arginine to
citrulline.64 If Etanercept treatment, through inhibition of
Figure 3. Dependency network displaying plasma metabolite relationships in psoriasis in the context of the noted metabolic perturbations between
(A) severe untreated psoriasis and control, (B) severe treated and severe untreated psoriasis, and (C) severe treated psoriasis and control patients.
Metabolites are connected based on partial correlation deﬁned relationships, and edge color and width display the direction and magnitude of the
FDR-adjusted Spearman rank order coeﬃcient of correlation (padj ≤ 0.05). Vertices represent metabolites, with the shape and color displaying
relative direction and statistical signiﬁcance (padj ≤ 0.05) of the metabolic change for each respective comparison (i.e., panel A displays changes in
severe psoriasis patients relative to controls). Metabolites are sized according to each comparison’s respective OPLS-DA model VIP (Figure 2), and
species in common in the exploratory and validation models’ selected feature sets are highlighted with thick black borders.
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TNFα, was impacting NOS activity, then shifts would be
expected in the ratio of the citrulline-to-arginine concentration
following treatment. However, a large reduction in all urea cycle
metabolites, including arginine and citrulline, was observed,
which does not support the modulation of NOS activity as a
mode of action of treatment. Similarly, there are no reported
mechanisms by which Etanercept may lead to reductions in
intermediates of glycine, serine, and threonine metabolism.
Etanercept could aﬀect these metabolites through modulation
of NOS, for example, by modulating the ﬂux of aspartate
between the urea cycle and threonine production. However, an
analysis of metabolite partial correlations (Figure 3) reveals that
aspartate levels are not directly linked to urea cycle
intermediates but instead to glutamate. Of the 20 metabolites
identiﬁed to shift with psoriasis, only cystathionine and cystine
were not normalized to healthy levels following Etanercept
treatment (Table 2 and Figure 3). Cystathionine was not
correlated with PASI scores prior to treatment (Table 3), which
may explain the lack of response and suggests a distinct
mechanism. The fact that circulating amino acid levels returned
to normal following anti-TNFα treatment in combination with
the strong correlation to PASI score (before and after
treatment) indicates that amino acid metabolism is a good
marker for anti-TNFα responsiveness, as indicated by Kapoor
et al.65
Psoriasis patients are at increased risk of metabolic syndrome
and diabetes,10 which share the common element of insulin
resistance. The excess amino acid availability can stimulate the
nutrient-sensitive mTOR/S6K pathway and inhibit serine
phosphorylation of insulin receptor substrate 1, which can
lead to an impairment in insulin-stimulated glucose disposal in
skeletal muscles and insulin-mediated inhibition of glucose
production.66 Accordingly, although the chronic inﬂammatory
status of psoriasis certainly plays a direct role in the
development of insulin resistance, the observed enhanced
circulating levels of amino acids suggest the hypothesis that the
mTOR/S6K pathway may contribute to this risk. However, the
validation of this tentative hypothesis warrants further
investigation.
■ CONCLUSIONS
Although the severity of psoriasis is clearly linked to levels of
circulating amino acids, the responsible mechanism(s) for the
observed shifts are unclear. The observed increased levels may
be due to keratinocyte hyperproliferation, increased proteolysis
due to cachexia, or other unknown pathways. During
hyperproliferation, the increased demand of protein building
units, and speciﬁcally proline, may lead to a strong shift in
amino acid proﬁles. Alternatively, it can be hypothesized that
individuals with severe psoriasis are cachetic. There is a paucity
of information on cachexia in psoriasis, but the majority of
studies report an increase in BMI, which is not aﬀected by
Etanercept treatment in this study. Accordingly, further
investigations are required to understand the signiﬁcance of
the observed amino acid shifts. It is clear that Etanercept
treatment signiﬁcantly shifts the metabolic proﬁles of psoriasis
patients, reversing the distinct psoriasis metabotype to that
observed in healthy individuals, suggesting that focused
metabolic proﬁling can be used to monitor patient response
to therapeutic intervention systematically. The strong correla-
tion of disease severity scoring with the metabolite levels
indicates that the observed metabolic shift reﬂects a trajectory
of disease progress rather than distinct disease pathologies. It is
also possible that circulating amino acid proﬁles could be used
as markers of both disease severity as well as responsiveness to
treatment.
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